Wolfe Research analyst Tim Anderson upgraded Merck to Outperform from Peer Perform with a $127 price target. The company "finally has a pipeline that is big enough to matter," the analyst tells investors in a research note. The firm says that given the various sources of optionality that lie ahead for Merck, either in the pipeline or in the base business, further multiple expansion of the shares is possible.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck provides update on Phase 3 MOVe-AHEAD trial evaluating LAGEVRIO
- Merck: FDA accepts for priority review sNDAs for PREVYMIS
- Merck announces sale of campus in Kenilworth, N.J.
- Merck’s Keytruda with chemotherapy shows improvements in Phase 3 trial
- AstraZeneca, Merck present final results from Phase III PROpel trial